Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Boston University |
---|---|
Information provided by: | Boston University |
ClinicalTrials.gov Identifier: | NCT00468299 |
The purpose of this study is to compare two combinations of drugs (mifepristone and misoprostol versus placebo and misoprostol) used for medical treatment for early pregnancy failure. We will compare the two combinations of medications to see which combination makes miscarriage happen faster. We hypothesize that there will be no difference in time to complete miscarriage between the two groups.
Condition | Intervention |
---|---|
Early Pregnancy Failure Miscarriage Fetal Demise Anembryonic Pregnancy |
Drug: mifepristone Drug: placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Treatment of Early Pregnancy Failure |
Estimated Enrollment: | 108 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Drug: placebo
this group does not receive mifepristone
|
2: Experimental
Receives mifepristone and misoprostol
|
Drug: mifepristone
200 mg mifepristone given along with 800 mcg misoprostol
|
The optimal method of treating Early Pregnancy Failure (EPF) is not certain. For many years, surgical management of EPF was the only treatment option.
Now there are multiple studies demonstrating the effectiveness of misoprostol for treating EPF. Most of the studies investigating medical treatment of EPF have evaluated efficacy at one week. We have found that many women do not want to wait for one week for an outcome of their medical treatment, and want resolution sooner. This has hampered the widespread utilization of medical therapy in our institution.
We propose a regimen of medical treatment for EPF with expeditious follow-up. We want to demonstrate the relative efficacy of two medication regimens for treatment of EPF by performing a randomized trial. One regimen will be 800μg buccal misoprostol alone and the other regimen will be 200mg mifepristone, orally, in addition to 800μg buccal misoprostol, simultaneously. The primary outcome will be complete abortion rates 24hours after medication administration. We hypothesize that mifepristone will not improve complete abortion rates at 24hrs.
Secondary outcomes include rates of abortion by medical treatment at one week, the indications for surgical intervention, relationship of progesterone levels and type of pregnancy failure to outcomes in the two groups. Another secondary objective is to assess satisfaction with the treatment process at the conclusion of pregnancy termination, and 3 weeks after the beginning of the process.
The majority of studies investigating medical treatment of EPF use vaginal misoprostol, but buccal use is increasing. We will use buccal misoprostol, which is widely used at our institution. We will assess the efficacy of this route of administration as well as assess patient acceptability of this method.
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Boston University | |
Boston, Massachusetts, United States, 02118 |
Principal Investigator: | Sarah J Betstadt, MD | Boston University |
Study Director: | Olivera Vragovic, MBA | Boston University |
Responsible Party: | Boston University ( Sarah Betstadt, MD ) |
Study ID Numbers: | H-25999 |
Study First Received: | May 1, 2007 |
Last Updated: | October 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00468299 History of Changes |
Health Authority: | United States: Institutional Review Board |
early pregnancy failure mifepristone misoprostol buccal |
miscarriage fetal demise anembryonic progesterone |
Pregnancy Complications Progesterone Contraceptive Agents Hormone Antagonists Contraceptives, Oral Misoprostol |
Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptive Agents, Female Mifepristone Abortion, Spontaneous Contraceptives, Postcoital Hormones |
Abortifacient Agents, Steroidal Contraceptives, Postcoital, Synthetic Pregnancy Complications Oxytocics Contraceptive Agents Hormone Antagonists Misoprostol Contraceptives, Oral Physiological Effects of Drugs Gastrointestinal Agents Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptive Agents, Female |
Mifepristone Reproductive Control Agents Abortifacient Agents, Nonsteroidal Luteolytic Agents Contraceptives, Postcoital Pharmacologic Actions Therapeutic Uses Anti-Ulcer Agents Abortifacient Agents Menstruation-Inducing Agents Contraceptives, Oral, Synthetic Abortion, Spontaneous |